Education
About Us
Working with TipRanks
Follow Us
Engene Holdings Inc. (ENGN)
:ENGN
ENGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.50 - $16.62
Previous CloseN/A
Volume16.79K
Average Volume (3M)36.91K
Market Cap
$203.91M
Enterprise Value$152.79M
Total Cash (Recent Filing)$81.52M
Total Debt (Recent Filing)$9.78M
Price to Earnings (P/E)―
Beta-1.99
Next Earnings
Jun 13, 2025EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.52
Shares Outstanding50,977,560
10 Day Avg. Volume53,045
30 Day Avg. Volume36,906
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.33
Forecast
1Y Price Target
$21.57Price Target Upside439.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Clinical DataEarly data indicate a promising clinical profile, with detalimogene achieving a 71% complete response (CR) at any time and a 47% CR at six months.
Market PositioningDetalimogene has a good chance of being widely adopted in community urologist practices due to its ease of use, administration, tolerability, safety, and efficacy.
Pipeline ExpansionThe LEGEND study in HR-NMIBC expanded to additional sites in Asia and Europe, which will facilitate the completion of enrollment in the pivotal cohort and additional cohorts.
Bears Say
Competitive LandscapeENgn's non-viral gene therapy asset detalimogene is particularly well-positioned to be an early-line treatment choice in the NMIBC space, but cross-trial comparisons with more advanced programs could affect its competitive standing.
Financial PerformanceResearch and Development costs of $20.0mm were above the consensus of $12.4mm, indicating higher than expected spending.
Stock ValuationInvestor sentiment has been influenced by cross-trial comparisons to more advanced programs—likely contributing to enGene’s stock trading near the lower end of its 52-week range.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ENGN FAQ
What was Engene Holdings Inc.’s price range in the past 12 months?
Engene Holdings Inc. lowest stock price was $3.50 and its highest was $16.62 in the past 12 months.
What is Engene Holdings Inc.’s market cap?
Engene Holdings Inc.’s market cap is $203.91M.
When is Engene Holdings Inc.’s upcoming earnings report date?
Engene Holdings Inc.’s upcoming earnings report date is Jun 13, 2025 which is in 60 days.
How were Engene Holdings Inc.’s earnings last quarter?
Engene Holdings Inc. released its earnings results on Mar 10, 2025. The company reported -$0.48 earnings per share for the quarter, missing the consensus estimate of -$0.368 by -$0.112.
Is Engene Holdings Inc. overvalued?
According to Wall Street analysts Engene Holdings Inc.’s price is currently Undervalued.
Does Engene Holdings Inc. pay dividends?
Engene Holdings Inc. does not currently pay dividends.
What is Engene Holdings Inc.’s EPS estimate?
Engene Holdings Inc.’s EPS estimate is -0.5.
How many shares outstanding does Engene Holdings Inc. have?
Engene Holdings Inc. has 50,977,560 shares outstanding.
What happened to Engene Holdings Inc.’s price movement after its last earnings report?
Engene Holdings Inc. reported an EPS of -$0.48 in its last earnings report, missing expectations of -$0.368. Following the earnings report the stock price went down -1.718%.
Which hedge fund is a major shareholder of Engene Holdings Inc.?
Currently, no hedge funds are holding shares in ENGN
---
enGene Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.57 (439.25% Upside)
$21.57 (439.25% Upside)
Blogger Sentiment
Bullish
ENGN Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 550.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $5.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 11.8%
Last 30 Days ▼ 11.8%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.42%
12-Months-Change
Fundamentals
Return on Equity
-44.21%
Trailing 12-Months
Asset Growth
206.07%
Trailing 12-Months
Company Description
Engene Holdings Inc.
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
---
ENGN Stock 12 Month Forecast
Average Price Target
$21.57
▲(439.25% Upside)
Technical Analysis
Ocugen
―
Cidara Therapeutics
―
Corvus Pharmaceuticals
―
Tevogen Bio Holdings
―
CARGO Therapeutics, Inc.
―
Best Analysts Covering ENGN
1 Year
1 Year Success Rate
0/6 ratings generated profit
1 Year Average Return
-47.62%
reiterated a buy rating last month
Copying Yanan Zhu's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -47.62% per trade.
---